SOTACPharmaceuticals
Sotac Pharmaceuticals Ltd — Cash Flow Statement
₹109.25
+0.00%
Sotac Pharmaceuticals Ltd Cash Flow Statement (Annual)
| Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
| Free Cash Flow | -33.91 Cr | -0.86 Cr | 2.85 Cr | -3.47 Cr |
| Issuance Of Capital Stock | 33.30 Cr | 1.79 Cr | 0.00 | 0.00 |
| Capital Expenditure | -17.79 Cr | -9.00 Cr | -3.50 Cr | -3.16 Cr |
| End Cash Position | 3.42 Cr | 9.68 Cr | 0.03 Cr | 0.27 Cr |
| Other Cash Adjustment Outside Changein Cash | -1000.00 | 1000.00 | — | — |
| Beginning Cash Position | 9.68 Cr | 0.08 Cr | 0.02 Cr | 0.43 Cr |
| Changes In Cash | -6.26 Cr | 9.61 Cr | 48000.00 | -0.16 Cr |
| Financing Cash Flow | 29.54 Cr | 13.14 Cr | -2.83 Cr | 3.38 Cr |
| Net Other Financing Charges | -4.88 Cr | 9.56 Cr | — | — |
| Interest Paid Cff | -1.70 Cr | -1.98 Cr | -0.53 Cr | -1.02 Cr |
| Net Common Stock Issuance | 33.30 Cr | 1.79 Cr | 0.00 | 0.00 |
| Common Stock Issuance | 33.30 Cr | 1.79 Cr | 0.00 | 0.00 |
| Net Issuance Payments Of Debt | 2.82 Cr | 3.76 Cr | -1.84 Cr | 4.40 Cr |
| Net Short Term Debt Issuance | -1.54 Cr | 3.11 Cr | -0.08 Cr | 2.49 Cr |
| Net Long Term Debt Issuance | 4.36 Cr | 0.65 Cr | -1.75 Cr | 1.91 Cr |
| Investing Cash Flow | -19.68 Cr | -11.67 Cr | -3.52 Cr | -3.23 Cr |
| Net Other Investing Changes | 0.13 Cr | — | — | — |
| Interest Received Cfi | 0.05 Cr | 0.05 Cr | 0.05 Cr | 0.06 Cr |
| Dividends Received Cfi | 50000.00 | 0.00 | — | — |
| Net Investment Purchase And Sale | -2.10 Cr | 0.00 | -0.06 Cr | -0.13 Cr |
| Net Business Purchase And Sale | 0.00 | -4.00 Cr | — | — |
| Purchase Of Business | 0.00 | -4.00 Cr | — | — |
| Net PPE Purchase And Sale | -17.78 Cr | -7.69 Cr | -3.50 Cr | -3.16 Cr |
| Sale Of PPE | 91000.00 | 1.31 Cr | — | — |
| Purchase Of PPE | -17.79 Cr | -9.00 Cr | -3.50 Cr | -3.16 Cr |
| Operating Cash Flow | -16.12 Cr | 8.14 Cr | 6.35 Cr | -0.31 Cr |
| Taxes Refund Paid | -2.09 Cr | -1.68 Cr | -1.86 Cr | -0.42 Cr |
| Change In Working Capital | -20.31 Cr | 1.57 Cr | 0.08 Cr | -1.61 Cr |
| Change In Other Current Liabilities | -2.76 Cr | 2.29 Cr | 0.02 Cr | 1.08 Cr |
| Change In Other Current Assets | -3.70 Cr | 2.42 Cr | -2.31 Cr | -2.56 Cr |
| Change In Payable | 3.50 Cr | -4.78 Cr | 9.43 Cr | 1.63 Cr |
| Change In Inventory | -4.37 Cr | -4.47 Cr | -1.60 Cr | -2.51 Cr |
| Change In Receivables | -11.71 Cr | 5.74 Cr | -6.27 Cr | 0.57 Cr |
| Other Non Cash Items | -0.65 Cr | 2.05 Cr | 0.47 Cr | 1.18 Cr |
| Depreciation And Amortization | 3.10 Cr | 2.28 Cr | 1.13 Cr | 2.59 Cr |
| Depreciation | 3.10 Cr | 2.28 Cr | 1.13 Cr | 2.59 Cr |
| Gain Loss On Investment Securities | -0.13 Cr | — | 1.84 Cr | — |
| Net Income From Continuing Operations | 3.96 Cr | 3.93 Cr | 4.69 Cr | -2.06 Cr |
| Issuance Of Debt | — | 3.76 Cr | — | — |
| Short Term Debt Issuance | — | 3.11 Cr | — | — |
| Long Term Debt Issuance | — | 0.65 Cr | — | — |
| Cash Dividends Paid | — | — | -0.46 Cr | — |
| Pension And Employee Benefit Expense | — | — | 0.00 | 0.00 |
| Gain Loss On Sale Of PPE | — | — | 0.00 | 0.00 |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Sotac Pharmaceuticals Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.